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Abstract Structural studies of plant and bacterial members of
the phospholipase D (PLD) superfamily are providing informa-
tion about the role of the conserved HKD domains in the struc-
ture of the catalytic center and the catalytic mechanism of
mammalian PLD isozymes (PLD1 and PLD2). Mutagenesis
and sequence comparison studies have also de¢ned the presence
of pleckstrin homology and phox homology domains in the
N-terminus and have demonstrated that a conserved sequence
at the C-terminus is required for catalysis. The N- and C-ter-
minal regions of PLD1 also contain interaction sites for protein
kinase C, which can directly activate the enzyme through a non-
phosphorylating mechanism. Small G proteins of the Rho and
ADP-ribosylation factor families also directly regulate the en-
zyme, with RhoA binding to a sequence in the C-terminus. Cer-
tain tyrosine kinases and members of the Ras subfamily of small
G proteins can activate the enzyme, but the mechanisms appear
to be indirect. The mechanisms by which agonists activate PLD
in vivo probably involve multiple pathways.
/ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. General properties of phospholipase D (PLD)
PLD is a widely distributed enzyme found in bacteria, fun-
gi, plants and animals. It has been implicated in several im-
portant cellular functions and, in mammals, is under the con-
trol of many hormones, neurotransmitters, growth factors and
cytokines. Its principal substrate is phosphatidylcholine and
its product, phosphatidic acid, is widely believed to have a
signaling role.
PLD is a member of a superfamily, which includes phos-
phatidylserine synthase, cardiolipin synthase, tyrosyl-DNA
phosphodiesterase, two bacterial endonucleases, a murine tox-
in of Yersinia pestis and two poxvirus envelope proteins [1].
These diverse proteins are denoted by the presence of one or
more HxKxxxxD motifs abbreviated to HKD. Mutagenesis of
this motif causes loss of catalytic function, and structural
studies of low Mr members of the PLD superfamily indicate
that the catalytic site is comprised of a dimer of two HKD
domains [1]. The linear structures of some members of the
PLD superfamily are shown in Fig. 1. They all show two
conserved sequences designated I and IV, which contain the
HKD motifs, and some have additional conserved sequences
(II and III).
There are two mammalian PLD isoforms (PLD1 and
PLD2) which occur as splice variants. These have four con-
served sequences (I^IV) (Fig. 1) and pleckstrin homology
(PH) and phox homology (PX) domains in tandem at their
N-termini [2]. These domains are implicated in phospholipid
and protein binding. The enzymes have an almost absolute
requirement for phosphatidylinositol 4,5-bisophosphate
(PIP2) for activity. There is evidence that PIP2 binds at the
PH domain and at a conserved sequence located between
conserved sequences II and III [3,4]. PLD1 and PLD2 are
membrane-associated but several domains and post-transla-
tional modi¢cations appear to be involved in membrane in-
teraction. The C-terminal four amino acids of mammalian
PLDs are completely conserved, and deletion, addition or
mutation of these residues causes loss of catalytic activity
[5,6]. The nature of the participation of the C-terminus in
catalysis is presently unknown. Deletion of the N-terminal
168 amino acids of PLD1 results in a large increase in basal
activity implying the existence of an inhibitory domain in this
region [7,8]. The exact location of this domain has not been
de¢ned.
There is no general agreement about where PLD1 and
PLD2 are localized in cells. This appears to be due to di¡er-
ences in cell type and methodology (tagging with GFP or
di¡erent epitopes, immuno£uorescence with di¡erent antibod-
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Fig. 1. Sequences of members of the PLD superfamily showing con-
served sequences (I^IV).
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ies). However, PLD1 appears to be localized to the Golgi or
perinuclear vesicular structures, whereas PLD2 appears to be
associated with the plasma membrane [1]. The enzymes may
also be present in caveolae and may co-localize with the actin
cytoskeleton. Both PLD1 and PLD2 are palmitoylated and
phosphorylated on Ser/Thr residues under basal conditions.
These modi¢cations are not required for catalytic activity,
but play a role in membrane association [1].
2. Regulation by protein kinase C
Early studies of the activation of PLD by phorbol esters in
various cell types implicated protein kinase C (PKC) in its
regulation. Inhibitors of PKC reduced agonist activation of
PLD activity, although the magnitude of the inhibition was
variable, depending on the agonist and cell type [9]. Other
approaches indicating the involvement of PKC included
down-regulation of the enzyme by prolonged treatment with
phorbol ester, and overexpression or antisense deletion of
speci¢c PKC isozymes [9]. In addition, overexpression of
phosphoinositide phospholipase C (PLC), which generates di-
acylglycerol and activates PKC, resulted in increased PLD
activity [10].
When the mammalian isozymes of PLD were cloned and
expressed, PLD1 was shown to be stimulated by PKCK in
vitro, whereas PLD2 was not a¡ected [11,12]. More detailed
studies showed that only the K- and L-isozymes of PKC could
activate recombinant PLD1 in vitro [11,13]. More surprising,
the activation occurred in the absence of ATP by a non-phos-
phorylating mechanism [11,13]. In fact, when ATP was added
to the reaction, phosphorylation of PLD1 was associated with
inhibition of enzyme activity [11,13]. Synergistic interaction
between PKCK and other small G proteins (Rho, ADP-ribo-
sylation factor (Arf)) that activate PLD was observed [11].
Deletional mutagenesis and binding studies have demon-
strated the presence of PKC interaction sites in both the
N- and C-terminal sequences of PLD1 [2,7,14]. Studies of
the sequences in PKCK required for activation of PLD have
shown that both the regulatory and catalytic domains of the
kinase play a role [15].
Stimulation of PKC by phorbol esters and many agonists in
vivo results in marked activation of PLD1 and, surprisingly,
of PLD2 also [2,7,8,11,16,17]. The mechanisms involved in the
activation of PLD1 and PLD2 in vivo are unclear. For exam-
ple, although treatment of cells with phorbol ester results in
phosphorylation of both isozymes on Ser and Thr residues,
there is no clear evidence that this phosphorylation is respon-
sible for their activation [18]. For example, mutants of PKCK
that lack kinase activity do not induce phosphorylation of
PLD1 or PLD2 in vivo, but they still activate the enzyme,
suggesting mechanisms that do not involve phosphorylation
(Tianhui Hu, Jun Song Chen and J.H.E., unpublished obser-
vations). In summary, these ¢ndings suggest that agonists that
activate PLC cause membrane translocation and activation of
conventional PKC isozymes which, in turn, activate PLD. The
activation of PLD probably occurs because of direct interac-
tion of the isozymes with PLD rather than direct phosphory-
lation.
3. Regulation by small G proteins of the Rho family
There is much evidence that RhoA, Rac1 and Cdc42Hs
activate PLD1, but not PLD2 [11,12,19,20]. For example
addition of GTPQS-activated forms of these proteins to re-
combinant PLD1 in vitro results in its activation. RhoA is
the most e⁄cacious, but Rac1 and Cdc42Hs cause signi¢-
cant activation [19]. The geranylgeranylated forms of the
G proteins have higher activity than the unmodi¢ed forms
[19]. The stimulation of PLD1 involves the activation loop
(Switch I) of the G proteins, and residues in the Switch II
region and the insert helix determine their relative e⁄cacies
[19,21]. The interaction site for RhoA on PLD1 has been
localized to sequences in the C-terminus by binding and ac-
tivity measurements [22^24]. In the absence of information
about the three-dimensional structure of PLD1, it is not
known how binding of Rho proteins to these sequences re-
sults in activation of the enzyme or in synergistic interaction
with PKCK.
An in vivo role for RhoA in the activation of PLD1 has
been demonstrated for agonists whose receptors couple to the
heterotrimeric G protein G13 [17,24,25]. This role seems lim-
ited in comparison to the many agonists whose receptors ac-
tivate phosphoinositide PLC and PKC. Studies of mutant
forms of PLD1 in which the RhoA interaction sites have
been mutated have indicated that the enzyme can be activated
in vivo by direct binding of RhoA [17,24]. However, RhoA
may also indirectly regulate the enzyme because of its e¡ects
on phosphatidylinositol 4-P 5-kinase, which is the enzyme that
synthesizes PIP2 [26^28]. The in vivo e¡ects of RhoA on PLD
activity have been explored through the use of clostridial tox-
ins (C3 exoenzyme and toxin B) [29,30] and also by trans-
fection of dominant negative and constitutively active forms
of RhoA and Rac1 [1]. However, these agents do not dis-
tinguish between direct and indirect e¡ects of these small
G proteins on PLD.
4. Regulation by small G proteins of the Arf family
Arf was the ¢rst direct regulator of PLD1 to be recog-
nized. All mammalian isoforms of Arf can activate the en-
zyme in vitro and the myristoylated forms are more active
than the unmodi¢ed forms [31^33]. PLD2 shows little or no
response to Arf [12,20]. The interaction site on ARF for PLD
has been localized to the N-terminus [34,35], but it is not
known where ARF binds on PLD. Interestingly, truncation
of the ¢rst 308 amino acids of PLD2 renders it capable of
responding to Arf [20]. In contrast to the many studies show-
ing that PLD can be activated by Arf1 in vitro, there is less
information on the role of this small G protein in the acti-
vation of the enzyme in vivo. On the other hand Arf 6 is
principally localized to the plasma membrane [36^39] where
it probably regulates PLD. For example, stimulation of chro-
ma⁄n cells results in translocation of Arf6 to the plasma
membrane and a concurrent increase in PLD activity [39].
Furthermore, the activation of PLD is blocked by addition
of a myristoylated peptide corresponding to the N-terminus
of Arf6 [39]. The use of brefeldin A to explore the role of Arf
in agonist activation of PLD in vivo has given variable
results. This is probably because this compound inhibits
some, but not all, of the guanine nucleotide exchange factors
for Arfs [40]. As for RhoA, Arfs 1 and 6 have been reported
to activate phosphatidylinositol 4-P 5-kinase and this could
also control the activity of PLD through increases in PIP2
[41,42].
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5. Regulation by tyrosine phosphorylation
Agents that increase reactive oxygen species can activate
PLD through tyrosine phosphorylation. Thus H2O2 in the
presence of vanadate induces both activation and tyrosine
phosphorylation of PLD1 in several cell types [43^46]. Tyro-
sine kinase inhibitors also inhibit the activation of PLD in-
duced by many agonists whose receptors couple to heterotri-
meric G proteins [1]. However, the tyrosine kinases involved
and the exact relationship between tyrosine phosphorylation
of the enzyme and its increased catalytic activity remain un-
clear. As described below, v-Src can activate PLD [47], but the
e¡ect is mediated by members of the Ras subfamily of small
G proteins.
6. Regulation by small G proteins of the Ras family
Ras does not directly activate PLD, but there is evidence
that Ras mediates the activation of PLD induced by v-Src in
vivo [48]. Further work has shown that RalA, a member of
the Ras subfamily, is also required [49]. The precise interac-
tions between Ras, RalA and PLD1 that lead to activation of
the enzyme are not clear, but may involve Arf [50,51]. A role
for Ras and Ral in PLD activation has also been indicated
through the use of clostridial toxins that inactivate Ral, and
by transfection with dominant negative forms of Ras and
RalA [52,53].
7. Conclusions
Some information about the three-dimensional structure of
mammalian PLDs is emerging from reports of the crystal
structure of plant and bacterial members of the PLD super-
family. These reports have provided insights into the structure
of the catalytic center and the catalytic mechanism. However,
these proteins are small and do not possess the N- and C-ter-
minal domains of mammalian PLDs at which regulatory pro-
teins interact. The intracellular localizations of PLD1 and
PLD2 need better de¢nition to help clarify their mechanisms
of regulation. PKC is a major regulator of PLD activity in
vivo and in vitro, and in vitro evidence indicates that it can
act through a direct non-phosphorylating mechanism. There is
also evidence for a non-phosphorylating mechanism in vivo.
However, PLD1 and PLD2 can be phosphorylated on Ser,
Thr and Tyr residues in vivo and the signi¢cance of this in
terms of their activities and intracellular localization needs to
be clari¢ed. Rho family G proteins activate PLD1 in vitro and
are involved in the regulation of this enzyme by several ago-
nists in vivo. However, the extent to which the enzyme is
activated by direct interaction with Rho proteins versus
changes in PIP2 levels needs to be de¢ned. Although all Arf
family G proteins activate PLD1 in vitro, the evidence for an
in vivo role is strongest for Arf 6. With respect to tyrosine
kinases, studies with inhibitors of these kinases suggest a role
for tyrosine phosphorylation in the activation of PLD by
many agonists. Ras and Ral appear to play a role in the
regulation of PLD by tyrosine kinases. However, the mecha-
nisms involved appear to be complex and further work is
needed to clarify these.
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